Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Feinberg

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Journal of Virology|January 25, 2008
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesisShari N Gordon, Richard M Dunham, Jessica C Engram, et al.
Blood|March 9, 2006
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virusRichard Dunham, Paola Pagliardini, Shari Gordon, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|April 17, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|October 5, 2023
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Vaccines|October 27, 2022
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical TrialsChristopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
Science (New York, N.Y.)|January 17, 2004
Public health. A sound rationale needed for phase III HIV-1 vaccine trialsDennis R Burton, Ronald C Desrosiers, Robert W Doms, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
Ebiomedicine|March 29, 2025
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trialsChristopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Journal of Virology|January 25, 2008
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesisShari N Gordon, Richard M Dunham, Jessica C Engram, et al.
Blood|March 9, 2006
The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virusRichard Dunham, Paola Pagliardini, Shari Gordon, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|April 17, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|October 5, 2023
Author Correction: A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Vaccines|October 27, 2022
Nonhuman Primates Are Protected against Marburg Virus Disease by Vaccination with a Vesicular Stomatitis Virus Vector-Based Vaccine Prepared under Conditions to Allow Advancement to Human Clinical TrialsChristopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
Science (New York, N.Y.)|January 17, 2004
Public health. A sound rationale needed for phase III HIV-1 vaccine trialsDennis R Burton, Ronald C Desrosiers, Robert W Doms, et al.
Ebiomedicine|August 1, 2022
Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimeraAmy S Espeseth, Maoli Yuan, Michael Citron, et al.
Ebiomedicine|March 29, 2025
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trialsChristopher L Cooper, Gavin Morrow, Maoli Yuan, et al.
Pageof 6